Why Europe’s CDMO Sector Must Learn to Dance with Disruption
For CDMOs, the storms of de-industrialization, Brexit, and the Biosecure Act are not existential threats but the very winds that can propel them forward.
False
For CDMOs, the storms of de-industrialization, Brexit, and the Biosecure Act are not existential threats but the very winds that can propel them forward.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
August 18, 2026
10 min read
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
August 7, 2026
7 min read
Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier
August 6, 2026
8 min read
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
August 4, 2026
4 min read
A recent multimillion-dollar freezer failure highlights the urgent need for real-time visibility across the pharmaceutical supply chain
False
Affiliations:
Specialties:
Areas of Expertise: